絞り込み

16546

広告

「"Lacouture ME"[Author]」の検索結果

199件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment.

Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study.

Safety and Efficacy of Retreating with Immunotherapy After Immune-Related Adverse Events in Patients with NSCLC.

Li-Fraumeni Syndrome-Related Malignancies Involving the Genitourinary Tract: Review of a Single-Institution Experience.

Pruritus Associated with Targeted Anticancer Therapies and Their Management.

CME Part 2: Hair disorders in cancer survivors Persistent chemotherapy-induced alopecia, persistent radiotherapy-induced alopecia, and hair growth disorders related to endocrine therapy or cancer surgery.

CME Part 1: Hair disorders in cancer patients.

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.

Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer.

Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.

Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.

The microbial flora of taxane therapy-associated nail disease in cancer patients.

SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.

Inflammatory dermatoses, infections and drug eruptions are the most common skin conditions in hospitalized cancer patients.

Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.

A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります